The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Anderson, Ronald ^a   Theron, Annette J ^a,b   Steel, Helen C ^a   Durandt, Chrisna ^a   Tintinger, Gregory R ^a   Feldman, Charles ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CD18 ANTIGEN; CYCLIC AMP; ELASTASE; FORMOTEROL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INDACATEROL; LEUKOTRIENE B4; REACTIVE OXYGEN METABOLITE; SALBUTAMOL; THROMBOCYTE ACTIVATING FACTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; INDAN DERIVATIVE; PANCREATIC ELASTASE; QUINOLONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CHEMOLUMINESCENCE; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ACTIVATION; LUNG FIBROBLAST; MAST CELL; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL SURVIVAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; OXYGEN CONSUMPTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ALBUTEROL; CALCIUM; CELL SURVIVAL; CYCLIC AMP; CYTOSOL; ETHANOLAMINES; FLOW CYTOMETRY; HUMANS; INDANS; LEUKOTRIENE B4; NEUTROPHILS; OXYGEN CONSUMPTION; PANCREATIC ELASTASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; REACTIVE OXYGEN SPECIES;

EID: 84896914034     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/105420     Document Type: Article

References (35)

1. Cazzola M., Page C. P., Rogliani P., Matera M. G., β -agonist therapy in lung disease. American Journal of Respiratory and Critical Care Medicine 2013 187 7 690 696
2. Sears M. R., The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility? Thorax 2013 68 2 195 198 10.1136/thoraxjnl-2012-202414
3. Johnson M., Effects of β 2-agonists on resident and infiltrating inflammatory cells. Journal of Allergy and Clinical Immunology 2002 110 6 S282 S290 2-s2.0-0036907527 10.1067/mai.2002.129430 (Pubitemid 35471717)
4. Serezani C. H., Ballinger M. N., Aronoff D. M., Peters-Golden M., Cyclic AMP: master regulator of innate immune cell function. American Journal of Respiratory Cell and Molecular Biology 2008 39 2 127 132 2-s2.0-48649087006 10.1165/rcmb.2008-0091TR
5. Theron A. J., Steel H. C., Tintinger G. R., Feldman C., Anderson R., Can the anti-inflammatory activities of β 2-agonists be harnessed in the clinical setting? Journal of Drug Design, Development and Therapy 2013 2013 7 1387 11398 S50995 10.2147/DDDT.S50995
6. Matthay M. A., Brower R. G., Carson S., Douglas I. S., Eisner M., Hite D., Holets S., Kallet R. H., Liu K. D., MacIntyre N., Moss M., Schoenfeld D., Steingrub J., Thompson B. T., Randomized, placebo-controlled clinical trial of an aerosolized β 2-agonist for treatment of acute lung injury. American Journal of Respiratory and Critical Care Medicine 2011 184 5 561 568 2-s2.0-79960430979 10.1164/rccm.201012-2090OC
7. Smith F. G., Perkins G. D., Gates S., Young D., McAuley D. F., Tunnicliffe W., Khan Z., Lamb S. E., Effect of intravenous β -2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. The Lancet 2012 379 9812 229 235 2-s2.0-84856102590 10.1016/S0140-6736(11)61623-1
8. Barnes P. J., Effect of β -agonists on inflammatory cells. Journal of Allergy and Clinical Immunology 1999 104 2, part 2 S10 S17 2-s2.0-0032886819
9. Ray S. M., McMillen J. C., Treadway S. A., Helmer R. S., Franks A. S., Indacaterol: a novel long-acting β (2)-agonist. Pharmacotherapy 2012 32 5 456 474 10.1002/j.1875-9114.2012.01025.x
10. Han J., Dai L., Zhong N., Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulmonary Medicine 2013 13, article 26
11. De Coupade C., Gear R. W., Dazin P. F., Sroussi H. Y., Green P. G., Levine J. D., β 2-adrenergic receptor regulation of human neutrophil function is sexually dimorphic. British Journal of Pharmacology 2004 143 8 1033 1041 2-s2.0-11244316250 10.1038/sj.bjp.0705972 (Pubitemid 40065504)
12. Hoenderkos K., Condliffe A., The neutrophil in chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology 2013 48 5 531 539
13. Barnes P. J., New molecular targets for the treatment of neutrophilic diseases. Journal of Allergy and Clinical Immunology 2007 119 5 1055 1062 2-s2.0-34247500507 10.1016/j.jaci.2007.01.015 (Pubitemid 46654167)
14. Tannheimer S. L., Wright C. D., Salmon M., Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts. Respiratory Research 2012 13, article 28 2-s2.0-84858842750 10.1186/1465-9921-13-28
15. Scola A.-M., Loxham M., Charlton S. J., Peachell P. T., The long-acting β -adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. British Journal of Pharmacology 2009 158 1 267 276 2-s2.0-69249214018 10.1111/j.1476-5381.2009.00178.x
16. Gravett C. M., Theron A. J., Steel H. C., Tintinger G. R., Cockeran R., Feldman R., Anderson C., Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. The European Respiratory Journal 2010 36 6 1417 1424 2-s2.0-78649756979 10.1183/09031936.00157409
17. 2+ indicators with greatly improved fluorescence properties. The Journal of Biological Chemistry 1985 260 6 3440 3450 2-s2.0-0021895138 (Pubitemid 15114340)
18. Anderson R., Mahomed A. G., Calcium efflux and influx in f-met-leu-phe (fMLP)-activated human neutrophils are chronologically distinct events. Clinical and Experimental Immunology 1997 110 1 132 138 2-s2.0-9844231490 (Pubitemid 27428526)
19. Steel H. C., Anderson R., Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cytosolic calcium. British Journal of Pharmacology 2002 136 1 81 89 2-s2.0-0036257892 (Pubitemid 34499319)
20. Cazzola M., Matera M. G., Emerging inhaled bronchodilators: an update. European Respiratory Journal 2009 34 3 757 769 2-s2.0-70349090618 10.1183/09031936.00013109
21. Mak J. C. W., Chan-Yeung M. M. W., Reactive oxidant species in asthma. Current Opinion in Pulmonary Medicine 2006 12 1 7 11 2-s2.0-33646835914 10.1097/01.mcp.0000198067.50457.71 (Pubitemid 44378571)
22. Lee K.-Y., Ho S.-C., Lin H.-C., Lin S.-M., Liu C.-Y., Huang C.-D., Wang C.-H., Chung K. F., Kuo H.-P., Neutrophil-derived elastase induces TGF- β 1 secretion in human airway smooth muscle via NF- B pathway. American Journal of Respiratory Cell and Molecular Biology 2006 35 4 407 414 2-s2.0-33749189340 10.1165/rcmb.2006-0012OC (Pubitemid 44477641)
23. Li Q., Zhou X., Yu H., Nie X., Xu X., Roles of ROS/TACE in neutrophil elastase-induced mucus hypersecretion in NCI-H292 airway epithelial cells. European Cytokine Network 2010 21 3 177 185 2-s2.0-77957342049 10.1684/ecn.2010.0195
24. Ohnishi H., Miyahara N., Gelfand E. W., The role of leukotriene B4 in allergic diseases. Allergology International 2008 57 4 291 298 2-s2.0-59549104762 10.2332/allergolint.08-RAI-0019
25. Lee I. T., Yang C. M., Role of NADH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochemical Pharmacology 2012 84 5 581 590 10.1016/j.bcp.2012.05.005
26. Gaggar A., Hector A., Bratcher P. E., Mall M. A., Griese M., Hartl D., Series "matrix metalloproteinases in lung health and disease": the role of matrix metalloproteinases in cystic fibrosis lung disease. The European Respiratory Journal 2011 38 3 721 727 2-s2.0-80053063761 10.1183/09031936. 00173210
27. Sandhaus R. A., Torino G., Neutrophil elastase-mediated lung disease. COPD 2013 10, supplement 1 60 63 10.3109/15412555.2013.764403
28. Anderson R., Goolam Mahomed A., Theron A. J., Ramafi G., Feldman C., Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils. British Journal of Pharmacology 1998 124 3 547 555 2-s2.0-15144342064 10.1038/sj.bjp.0701849 (Pubitemid 28254512)
29. Brunskole Hummel I., Reinartz M. T., Kälble S., Dissociations in the effects of β 2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity. PLoS ONE 2013 8 5 e64556
30. Bosmann M., Grailer J. J., Zhu K., Anti-inflammatory effects of β 2 adrenergic receptor agonists in experimental acute lung injury. The FASEB Journal 2012 26 5 2137 2144
31. Black J. L., Oliver B. G. G., Roth M., Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting β -agonists. Chest 2009 136 4 1095 1100 2-s2.0-70350120599 10.1378/chest.09-0354
32. Chung K. F., Caramori G., Adcock I. M., Inhaled corticosteroids as combination therapy with β -adrenergic agonists in airways disease: present and future. European Journal of Clinical Pharmacology 2009 65 9 853 871 2-s2.0-69249222635 10.1007/s00228-009-0682-z
33. Ridolo E., Montagni M., Olivieri E., Riario-Sforza G. G., Incorvaia C., Role of indacaterol and the newer very long-acting β 2-agonists in patients with stable COPD: a review. International Journal of Chronic Obstructive Pulmonary Disease 2013 2013 8 425 432 10.2147/COPD.S49179
34. Rossi A., Polese G., Indacaterol: a comprehensive review. International Journal of Chronic Obstructive Pulmonary Disease 2013 2013 8 353 363 10.2147/COPD.S21625
35. Khindri S., Sabo R., Harris S., Woessner R., Jennings S., Drollmann A. F., Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulmonary Medicine 2011 11, article 31 2-s2.0-79957457853 10.1186/1471-2466-11- 31